Quantcast
Last updated on April 16, 2014 at 7:15 EDT

Latest ARN-509 Stories

2012-10-01 02:31:07

SAN DIEGO, Oct. 1, 2012 /PRNewswire/ -- Aragon Pharmaceuticals Inc., a leader in developing drugs for hormone driven cancers, announced new data from an ongoing, open-label, multicenter Phase II study of ARN-509, the company's 2nd generation androgen receptor antagonist, demonstrating promising results of ARN-509 in three separate patient populations with castration resistant prostate cancer (CRPC). Data were presented at the European Society for Medical Oncology 2012 Annual Meeting in...